TransCode Therapeutics published a study in Cancers demonstrating that their lead candidate, TTX-MC138, significantly improved survival in a preclinical breast cancer bone metastasis model by targeting microRNA-10b, a key driver of metastasis. The treatment was well tolerated with no systemic toxicity and reduced metastatic progression markers. This supports the potential of TTX-MC138 as a novel therapy for metastatic cancers, with ongoing clinical trials focusing on colorectal cancer and future applications in other metastatic tumors.
Sandisk and Kioxia announced plans to invest over $31 billion in their memory manufacturing facilities in Japan. This investment represents about 60% of what they have spent there over the past 25 years, signaling a major expansion in their productio...
Strategy purchased 4,603 Bitcoin for $369.7 million at an average price of $80,318 per coin, increasing its total Bitcoin holdings to 845,050 BTC. This purchase price is above the company's average cost basis of $75,412 per Bitcoin. The acquisition w...
Strategy purchased 4,603 Bitcoin for $369.7 million at an average price of $80,318 per coin, increasing its total holdings to 845,050 BTC. This average purchase price is above their overall cost basis of $75,412 per Bitcoin. Bitcoin's price hovered n...
Since Tim Cook became Apple's CEO in 2011, a $5,000 investment in the company would have grown by 2,741.55% to about $142,077 by 2026, vastly outperforming the S&P 500's 551.55% gain. Cook expanded Apple's product line, boosted services revenue, and ...
Spot gold prices fell 0.36% to around $4,438 an ounce as investors weighed higher odds of a September Federal Reserve rate hike and renewed geopolitical tensions in the Strait of Hormuz. Meanwhile, spot silver rose 0.91% to about $66.86, supported by...
